RecruitingPhase 2NCT06511011

Chinese Medicine in Treating Insomnia

Efficacy and Safety of Modified Suan ZaoRen Tang-TianWang BuXin Dan in the Treatment of Chronic Insomnia: A Randomized, Double-blinded, Placebo-controlled Trial


Sponsor

Chinese University of Hong Kong

Enrollment

76 participants

Start Date

Sep 25, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This is a randomized, double-blinded, placebo-controlled clinical trial. Eligible participants will randomized into either treatment group (CM granules) or placebo group (placebo granules) for 6 weeks, followed by a post-treatment visit at week 9. The primary outcome is the change in Pittsburgh Sleep Quality Index (PSQI) at week 6.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Modified Suan ZaoRen Tang-TianWang BuXin Dan and a drug called Placebo for people with insomnia chronic. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGModified Suan ZaoRen Tang-TianWang BuXin Dan

Chinese medicine granules for 6 weeks

DRUGPlacebo

Placebo granules for 6 weeks


Locations(1)

Hong Kong Institute of Integrative Medicine

Shatin, Hong Kong

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06511011


Related Trials